Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02115, USA.
Cell Commun Signal. 2014 Apr 7;12:25. doi: 10.1186/1478-811X-12-25.
Signaling through vascular endothelial growth factor C (VEGF–C) and VEGF receptor 3 (VEGFR-3) plays a central role in lymphangiogenesis and the metastasis of several cancers via the lymphatics. Recently, the Slit2/Robo4 pathway has been recognized as a modulator of vascular permeability and integrity. Signaling via the Robo receptor inhibits VEGF-mediated effects; however, its effects on lymphatic endothelial cell function have not been well characterized.
We found that pretreatment with Slit2N, an active fragment of Slit2, inhibited VEGF-C-mediated lung-derived lymphatic endothelial cell (L-LEC) proliferation, migration, and in vitro tube formation. Slit2N induced the internalization of VEGFR-3, which blocked its activation, and inhibited the activation of the PI3K/Akt pathway by VEGF-C in L-LECs. Moreover, we found that inhibition of VEGF-C-induced effects by Slit2N was Robo4-dependent.
These results indicate that Slit2N/Robo4 modulates several key cellular functions, which contribute to lymphangiogenesis, and identify this ligand-receptor pair as a potential therapeutic target to inhibit lymphatic metastasis of VEGF-C-overexpressing cancers and manage lymphatic dysfunctions characterized by VEGF-C/VEGFR-3 activation.
血管内皮生长因子 C(VEGF-C)和血管内皮生长因子受体 3(VEGFR-3)通过淋巴管信号通路在淋巴管生成和多种癌症转移中发挥核心作用。最近,Slit2/Robo4 信号通路被认为是血管通透性和完整性的调节剂。Robo 受体的信号转导抑制了 VEGF 介导的作用;然而,其对淋巴管内皮细胞功能的影响尚未得到很好的描述。
我们发现,Slit2N(Slit2 的活性片段)预处理抑制了 VEGF-C 介导的肺来源的淋巴管内皮细胞(L-LEC)增殖、迁移和体外管形成。Slit2N 诱导 VEGFR-3 的内化,从而阻断其激活,并抑制 VEGF-C 在 L-LEC 中激活 PI3K/Akt 通路。此外,我们发现 Slit2N 抑制 VEGF-C 诱导的作用依赖于 Robo4。
这些结果表明 Slit2N/Robo4 调节了几个关键的细胞功能,这些功能有助于淋巴管生成,并将这个配体-受体对鉴定为抑制 VEGF-C 过表达癌症的淋巴转移和管理以 VEGF-C/VEGFR-3 激活为特征的淋巴功能障碍的潜在治疗靶点。